Effect of PEEP on Lung Recruitment and Homogeneity Over Time in Moderate to Severe ARDS
NCT ID: NCT03140579
Last Updated: 2022-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2018-06-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It will do this by comparing the homogeneity of ventilation and recruitment prior to a patient being ventilated on APRV, and at 30, 60 and 120 minutes after starting APRV.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasabilty and Physiological Effects of a Ventilation Strategy Combining PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures in ARDS Patients.
NCT05337059
Airway Pressure Release Ventilation in Acute Lung Injury
NCT00750204
Impact of PEEP Trials on Ventilation-Perfusion Matching in ARDS Patients
NCT06823804
Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome
NCT00527813
Assessment of the PEEP Responsiveness to Titrate End-expiratory Pressure and of the Need for Muscle Relaxation During Prone Positioning in Moderate-to-severe Acute Respiratory Distress Syndrome: A Master Protocol
NCT06849570
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
APRV is a mode of inverse ventilation, where high levels of PEEP are maintained with brief releases of pressure, and has been proposed as an appropriate method of ventilation in patients with ARDS.
This study will assess homogeneity of ventilation and recruitment in 15 patients before APRV is started, and 30, 60 and 120 mins after commencing APRV. It will do this using Electrical Impedance Tomography (EIT), nitrogen wash in/wash out technique, and lung strain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APRV
Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight \> 35 Kg and BMI \< 40
* Informed consent according to local regulations
* Hemoglobin ≥ 70 g/dl
* Haemodynamically stable \> 4 hours
* Moderate to severe ARDS (PaO2/FIO2 \< 26.6 kPa with positive end-expiratory pressure (PEEP) \> 5 cmH2O) as per Berlin definition of ARDS
Exclusion Criteria
* Suspected pregnancy (negative pregnancy test required for women of child-bearing potential)
* Open abdomen
* Documented or suspected raised intracranial pressure
* Active air leak (pneumothorax, pneumomediastinum, subcutaneous emphysema)
* Morbid obesity BMI \> 40
* Recent \< 1 week cardiac or thoracic surgery
* Unstable thorax and sternum with paradoxical chest wall movement
* Severe Chronic Respiratory Disease (COPD) - GOLD 3 or 4 emphysema with bullae
* Severe smoking (\> 40 pack-year history)
* Liver Failure: Child-Pugh Class C
* Massive ascites
* Lung fibrosis
* Severe cardiac disease (one of the following): New York Heart Association Class III or IV, acute coronary syndrome or persistent ventricular tachyarrhythmias
* Sickle cell disease
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guy's and St Thomas' NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luigi Camporota
Role: PRINCIPAL_INVESTIGATOR
Guy's and St Thomas' NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guys and St Thomas NHS Foundation
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
123456789
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.